NCT01626976View on ClinicalTrials.gov

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy
Interventions
DRUG

PF-06282999

Solution, doses range from 20 to 200 mg, single dose

DRUG

Placebo

Solution, single dose

DRUG

PF-06282999

Methylcellulose suspension, doses range 125 to 500 mg, single dose

DRUG

Placebo

suspension, single dose

DRUG

PF-06282999

Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose

DRUG

Placebo

suspension, single dose

DRUG

PF-06282999

Methylcellulose or simethicone suspension, 500 mg dose, single dose

DRUG

Placebo

suspension, single dose

DRUG

PF-06282999

Simethicone or methylcellulose suspension, up to 1500 mg, single dose

DRUG

Placebo

suspension, single dose

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01626976 - A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects | Biotech Hunter | Biotech Hunter